Novel hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
AssigneeCuraGen Corporation
InventorsCatherine Burgess, Richard A. Shimkets, Corine Vernet, Ferenc L. Boldog, Meiji Yang, William J. La Rochelle, Stacey Minskoff
Life of this patent
Estimating the term…
Abstract
The present invention provides HDGFX, a novel isolated polypeptide, as well as a polynucleotide encoding HDGFX and antibodies that immunospecifically bind to HDGFX or any derivative, variant, mutant, or fragment of the HDGFX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the HDGFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
Claims22
An isolated nucleic acid molecule encoding HDGFX, said molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 85% identical to SEQ ID NO:2, or the complement of said nucleic acid molecule.
3-27. Canceled.
A composition comprising a therapeutically or prophylactically effective amount of a composition selected from the group consisting of:
- a) an isolated nucleic acid molecule encoding HDGFX, said molecule comprising a nucleotide sequence encoding a polypeptide having a sequence that is at least 85% identical to SEQ ID NO:2, or the complement of said nucleic acid molecule;
- b) an isolated polypeptide at least 80% identical to a polypeptide selected from the group consisting of:
- i) a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- ii) a fragment of a polypeptide comprising an amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 6 contiguous amino acids of SEQ ID NO:2;
- iii) a derivative of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- iv) an analog of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- v) a homolog of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- and
- vi) a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- wherein the polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO:1 under stringent conditions;
- and
- c) an antibody that selectively binds to the polypeptide of step (b), and fragments, homologs, analogs, and derivatives of said antibody;
- and a pharmaceutically acceptable carrier.
A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the composition of claim 19.
The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a proliferative disorder, a differentiative disorder, and a tumorigenic disorder, wherein said therapeutic is selected from the group consisting of:
- a) an isolated nucleic acid molecule encoding HDGFX, said molecule comprising a nucleotide sequence encoding a polypeptide having a sequence that is at least 85% identical to SEQ ID NO:2, or the complement of said nucleic acid molecule;
- b) an isolated polypeptide at least 80% identical to a polypeptide selected from the group consisting of:
- i) a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- ii) a fragment of a polypeptide comprising an amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 6 contiguous amino acids of SEQ ID NO:2;
- iii) a derivative of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- iv) an analog of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- v) a homolog of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- and
- vi) a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence of SEQ ID NO:2;
- wherein the polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO:1 under stringent conditions;
- and
- c) an antibody that selectively binds to the polypeptide of step (b), and fragments, homologs, analogs, and derivatives of said antibody.
Dependencies are inferred from the claim text.